A-Synaptic

Asynaptic is a pre-clinical stage biotechnology company focused on developing novel therapies for Parkinson's disease and other neurodegenerative disorders. Founded by Dr. Peter Lansbury, a pioneer in the study of protein aggregation in the brain, the company targets the pathological forms of alpha-synuclein. Asynaptic's approach centers on identifying small molecules that can prevent the toxic aggregation of alpha-synuclein or promote its clearance to preserve synaptic function. By intervening at the earliest stages of protein misfolding, the company aims to provide disease-modifying treatments that slow or halt the progression of neurodegeneration.